info icon

This is a non-core endpoint: only basic statistics are computed.

Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)

C3_LYMPHNODES_SECONDARY_NAS_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector

Check conditions None

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C77
Cause of death: ICD-8 196
Cancer registry: Topography ICD-O-3 C77
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes 3

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

2139

diagram downward connector
C3_LYMPHNODES_SECONDARY_NAS_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF9

Similar endpoints

List of similar endpoints to Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 2139 932 1207
Unadjusted prevalence (%) 0.57 0.44 0.73
Mean age at first event (years) 56.08 52.91 58.52

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

Index endpoint: C3_LYMPHNODES_SECONDARY_NAS_EXALLC – Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)

Endpoint not on priority list, no data to show.